New drug cocktail aims to control rare blood cancer without lifelong treatment

NCT ID NCT07231952

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing a time-limited combination of three drugs—pirtobrutinib, venetoclax, and rituximab—in 40 patients newly diagnosed with Waldenström's macroglobulinemia, a rare blood cancer. The goal is to see if this regimen can achieve a very good partial response or better, potentially controlling the disease without requiring continuous therapy. Participants will take the drugs for a set period, then stop, with close monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pirtobrutinib, venetoclax, and rituximab
What this could lead to: If successful, this could offer a time-limited, chemotherapy-free treatment option that controls Waldenström's macroglobulinemia without needing lifelong therapy.
What could go wrong: This is a small, early-phase (Phase 2) study with only 40 participants. The combination may cause side effects like infections or blood cell issues, and it is not yet known if it works better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHOPLASMACYTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone lymphoplasmacytic lymphoma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOPLASMACYTIC LYMPHOMA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center (Data Collection Only)
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute (Data Collection and Specimen Analysis)
RECRUITING

Boston, Massachusetts, 02115, United States
Memoral Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Suffolk - Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.